


Erectile Dysfunction and Your Patients



The risk of erectile dysfunction is about 26 cases per 1,000 men annually, which increases with:

- age
- lower education
- diabetes
- heart disease
- hypertension,¹
- prostate cancer patients, regardless of treatment
- patients that have failed PDE-5 inhibitors

First-line Therapies for Erectile Dysfunction



¹ Johanne C., Araujo, A., Feldman, H., et. al.: Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol, **163**: 460-3, 2000.

Quality of Life Benefits

	Osbon ErecAid Vacuum Therapy System	Injections	Urethral Suppositories
Immediate Results	Yes	No	No
Patient Controlled	Yes	No	No
Easy to Use	Yes	No	No
Low Risk of Side Effects	Yes	No	No

“Vacuum Therapy is a viable alternative first line therapy. It’s cost effective and it works!” *W. Hellstrom, M.D.*

Choose a Viable, Alternative First Line Therapy for Patients With Erectile Dysfunction

If you have patients that have failed use of PDE-5 inhibitors or are unable to use PDE-5 inhibitors, the Osbon ErecAid® Vacuum Therapy System:

- Results in patient response to a vacuum erection device as well as to a PDE-5i²
- Restores sexual function in 9 out of 10 men, even diabetic and hypertensive patients
- Offers a non-invasive, drug-free alternative
- Provides an economical long-term solution
- Comes with an established 25+ year safety track record

When can we demonstrate 90% efficacy and satisfaction for a set of the ED patients in your clinic?

² Chen, J., Mabjesh, N., Greenstein, A. et. al.: Sildenafil versus the Vacuum Erection Device: Patient Preference. J Urol, **166**: 1780, 2001.

³ Witherington, R.: Vacuum constriction device for management of erectile dysfunction. J Urol **141**: 320-322, 1989

Distributed by:

 **timm**[®]
medical technologies, inc.
6585 City West Parkway
Eden Prairie, MN 55344 USA
www.timmmedical.com

PM08-0021, Rev.A 05/09